Articles tagged with Skin Tumors
A study found that male patients, those of older age, individuals with lower and higher socioeconomic status levels, and those speaking languages other than English were at higher risk for ED presentations after skin cancer diagnosis. The prevalence of ED presentation was 29% in Australian patients.
A new study found that a gene-based blood test can accurately predict skin cancer recurrence in stage III melanoma patients. The test measures circulating tumor DNA levels to identify those most likely to respond well to therapy.
A new study found that blocking an enzyme called HPGDS may be a way to improve melanoma treatment for patients who don't respond to immunotherapy. The enzyme promotes tumor growth and metastasis dissemination by blocking T-cell activity, but blocking it boosts the immune response.
Researchers develop innovative MSOT-AI technology to improve basal cell carcinoma diagnosis and surgical planning, reducing repeat procedures and improving patient outcomes. The technique captures detailed 3D views of tumours, enabling clearer insights into tumour boundaries.
A recent study by the CNIO Melanoma Group has discovered a mechanism by which melanomas evade immune system surveillance. The research found that melanoma cells secrete Midkine, a protein that reduces dendritic cell numbers and reprograms their function to promote tumour development.
A new type of antibody that stimulates the immune system to target cancer cells has shown promise in reducing tumor growth in treatment-resistant breast and ovarian cancers. The study found that the antibody, IgE, uniquely stimulated otherwise inactive immune cells to directly target HER2-expressing cancer cells.
Researchers found genetic changes not exclusive to tumours and skin patches, suggesting additional factors are necessary for tumour development. The study identified a pattern of mutations in the NF1 gene that may explain why nervous system tissues are commonly affected.
New cyanine-carborane salts show promise in eradicating metastatic breast cancer tumors with minimal side effects. The therapy targets specific proteins in cancer cells, allowing for precise killing of diseased cells while sparing healthy tissue.
A new combination therapy combining systemic interferon-I with local imiquimod application showed promising results in treating melanoma and breast cancer. The therapy activated the adaptive immune system to fight distant metastases, reducing tumor relapses and increasing sensitivity to checkpoint inhibitors.
Ewing sarcoma, a rare childhood cancer, is made more aggressive by the absence of STAG2 protein. This discovery provides potential biomarkers and therapeutic targets for treatment.
Researchers identified three subtypes of fibroblasts in skin cancer: myofibroblast-like RGS5+ CAFs, matrix CAFs (mCAFs), and immunomodulatory CAFs (iCAFs). The distribution of these subtypes varies with tumor aggressiveness. iCAFs produce signaling factors to activate immune cells, while mCAFs prevent T cell invasion.
A phase 2 clinical trial found that the combination of vidutolimod and nivolumab led to tumor control in 55% of patients, with higher levels of immune-related proteins detected in responders. The study also uncovered unique signatures of TLR9 activation and a link between gut microbiome and response to therapy.
Researchers at Tel Aviv University have discovered a new cancer mechanism that prevents the immune system from attacking tumors. The discovery was made by reversing this mechanism, which stimulates the immune system to fight cancer cells, including those resistant to prevailing forms of immunotherapy.
A remarkable clinical and metabolic response is reported in a metastatic BRAF V600E-mutated glomangiosarcoma treated with encorafenib and binimetinib. The combination of BRAF and MEK inhibitors achieves a long-lasting complete morpho-metabolic response in the patient.
Researchers used genomic technology to study Marjolin's ulcer, a rare and highly aggressive skin cancer that grows on chronic burn wounds. The study reveals insights into how keratinocytes switch their function to become cancerous, creating a fertile environment for tumor cells to grow and spread.
Researchers have developed a new method to detect melanoma using tumour-specific antibodies, which can accurately identify stage I and II melanoma patients. The study found that these antibodies showed high sensitivity and specificity in detecting melanoma, with an AUC value of up to 0.981.
A new clinical algorithm developed at the University of Gothenburg can accurately identify highly aggressive forms of basal cell carcinoma. The algorithm uses a combination of clinical and dermoscopic images to distinguish between low-risk and high-risk tumors, allowing for more effective treatment and better patient outcomes.
Researchers found correlations between MIF and DDT levels with patient survival outcomes in melanoma patients. Higher CD74:MIF and CD74:DDT levels were associated with improved survival and enrichment of inflammatory markers.
A distinct TNF-α signaling program has been identified as a key driver of epithelial cancer development, contributing to cell proliferation and invasion. The researchers found that this program is active in both normal tissues and tumors, but its level of activity correlates with tumor aggressiveness.
Researchers at Pohang University of Science & Technology have developed a method to boost bispecific antibody therapies in treating solid tumors. Using rhIL-7-hyFc, they found that bystander T cells can be activated by bispecific antibodies to destroy tumor cells, overcoming limitations of existing treatments.
Researchers found that GZ17-6.02 killed uveal melanoma cells by enhancing autophagy, inactivating key proteins, and reducing growth factors. The compound also interacted with doxorubicin and ERBB inhibitors to enhance tumor cell killing, suggesting potential as a single agent or combination therapy.
A novel therapy has been developed to reprogram macrophage immune cells, shifting their balance toward antitumor activity. The treatment, JHU083, blocks the use of glutamine in tumors, reducing growth and triggering cell death. It also boosts immune-activating macrophages, recruiting tumor-killing T-cells and natural killer cells.
Adult carriers of BAP1 tumor predisposition syndrome show a high incidence of onychopapillomas, a benign nail tumor. This finding suggests using these skin abnormalities to identify family members and patients with cancers associated with the syndrome.
The newly updated guidelines provide clinicians with the latest recommendations for staging and management of neuroendocrine tumors. The guidelines highlight recent changes for treating these tumors, including emerging molecular imaging techniques known as theranostics.
A mobile app using AI analyzes images of suspected skin lesions and provides guidance on whether they are melanoma or not. The app was tested in primary care and showed promising results, accurately diagnosing melanoma in all cases and determining harmless lesions with a high probability.
Research by Johns Hopkins Medicine suggests that increased stiffness in aging skin contributes to higher rates of melanoma metastasis by stimulating blood vessel growth and making them leaky. Treating older mice with drugs blocking ICAM1 prevented these changes, shrinking tumors and reducing metastasis.
Researchers at Johns Hopkins Medicine have reported promising results from a clinical trial testing a novel immunotherapy combination to target advanced, potentially lethal skin cancers in kidney transplant patients. Two out of six patients experienced complete tumor regression after adding a second checkpoint inhibitor to the regimen.
Researchers highlight difficulties in targeting metastatic tumors and propose two- and three-drug combinations to achieve effective tumor control. They also emphasize the need for simultaneous blocking of primary driving oncogene, evolving resistance mechanism, and secondary survival pathway.
A study by UC Davis Health found that a single dose of BCG reduced liver tumor burden and extended the survival of mice with liver cancer. The vaccine boosted the body's immunity, leading to tumor shrinkage and improved liver function.
Researchers have developed a new approach to treating cutaneous neurofibromas, a common skin tumor associated with neurofibromatosis type 1. By targeting the cAMP and Ras/MAPK pathways, this combination therapy may provide an enduring halt in the expansion of these tumors.
Scientists at Northwestern University and UCSF have developed a new technique to enhance the potency of human T cells against cancer. By studying mutations in malignant T cells, they were able to create T cells that can kill tumors derived from skin, lung, and stomach cancers in mice.
Researchers have engineered T cells with a mutation found in malignant lymphoma cells, making them more than 100 times potent at killing cancer cells. The new approach shows promise against solid tumors and could provide long-term immunity against cancer.
A team of researchers has developed a new visualization tool combining high-speed cameras and fluorescent injection to distinguish tumor tissue from normal tissue across cancer types. The technique, known as fluorescence lifetime (FLT) imaging, achieved an accuracy of over 97% in distinguishing tumor tissue from healthy tissue.
Recent research on gamma delta T cells has made significant progress in understanding their role in antitumor immune response. Key findings include the identification of various hidden mechanisms and a strong association between tumor-infiltrating gamma delta T cells and patient survival.
Researchers developed a minimally invasive microneedle platform capable of detecting protein biomarkers in response to immunotherapy against melanoma. The approach integrates with ultra-sensitive single-molecule detection and shows promise for effective drug screening and patient stratification.
A new study found that cetuximab plus radiotherapy is an active treatment option for locally advanced cutaneous squamous cell skin cancer, with an objective response rate of 83.2%. The treatment was well-tolerated, with most patients experiencing mild acneiform skin rash or fatigue.
A study published in the Journal of the American Academy of Dermatology found that curettage and cryosurgery is an effective and safe treatment method for basal cell carcinoma. The procedure involves scraping the lesion with a curette followed by freezing, resulting in good outcomes with minimal side effects.
Researchers developed a new method, photoacoustic spectral analysis (PASA), to analyze the tumor microenvironment without invasive procedures. The technique uses laser light and sound waves to identify different types of tumors with high accuracy.
Researchers have made a breakthrough in treating melanoma by adding an mRNA vaccine tailored to individual tumour genetics to common immunotherapy, significantly improving survival and disease recurrence rates. After two years, cancer-free survival increased to 78.6%, and the risk of death or cancer returning was reduced by 44%.
Researchers found that distant cancers alter liver function by inducing fat accumulation and inflammation in liver cells. The process involves secretion of extracellular vesicles containing fatty acids, which reprogram the liver to resemble fatty liver disease.
Researchers found that spinal cord stimulation reduced pain response in rats with human lung cancer tissue without compromising paclitaxel effectiveness. The study also showed SCS improved antitumor efficacy of paclitaxel, providing evidence for its potential as a companion treatment.
A new MYC inhibitor, Omomyc, has shown promising preclinical results in reducing melanoma tumor growth and metastatic capacity by halting the transcription of genes implicated in cell growth and proliferation. The study demonstrates a good prognostic gene signature in melanoma patients with this approach.
A new genomic catalogue of malignant peripheral nerve tumour-derived lines has challenged current diagnostic criteria, revealing misdiagnosed cell lines and a shared cell line masquerading as different types. The catalogue provides new information to develop precision therapies for these tumours.
Researchers have identified a biomarker signature that can predict which patients with kidney cancer will respond well to immunotherapy. The signature is based on the number of immune cells in and around tumors, the amount of dead cancer tissue, and mutations to a tumor suppressor gene called PBRM1.
Researchers analyzed autopsies of 14 patients with advanced melanoma, finding that changes to tumor DNA can cause resistance to treatment. The study sheds light on the final stages of cancer and may lead to new treatments for patients with advanced disease.
Researchers have discovered that cancer patients who don't respond to immunotherapy often lack CD5+ dendritic cells, which are essential for effective T cell activity. Boosting these cells may help more patients benefit from immunotherapy.
Researchers discovered a new approach to treating ependymoma, a rare childhood brain tumor, by targeting YAP fusion proteins. The study found that blocking the function of BRD4 gene expression regulator can prevent tumors from forming.
Researchers from Johns Hopkins Medicine have identified a novel mechanism of tumor formation in kidney cancers, highlighting the role of overactive mTORC1 signaling pathway and loss of the TSC tumor suppressor gene. Activation of microphthalmia transcription factors (MITF) family by unopposed mTOR signaling may lead to abnormal cell gr...
Researchers have made a breakthrough in precision oncology for patients with metastatic urothelial carcinoma, identifying that certain cell surface molecules decrease or are absent in these patients, making them resistant to the new drug enfortumab vedotin.
Researchers at UNIGE and LMU discovered that immune system's anti-tumour activity peaks in the morning. Tumours implanted at night grew faster than those implanted in the afternoon. Administering immunotherapy treatments early morning significantly enhanced their effectiveness, suggesting a new strategy for cancer treatment.
A study published in Nature reveals that cancer stem cells' miscommunication with their environment can trigger a self-perpetuating series of events leading to malignancy. Leptin signaling plays a surprising role in this process, which could be blocked to prevent tumor progression.
Researchers found a significant increase in Kaposi's sarcoma incidence among young Black men in the South, with rates jumping by 3.3% per year. The study suggests that HIV infection and social determinants like poverty and lack of access to medical care contribute to this disparity.
A study has identified a subset of early-stage melanoma patients with almost no risk of death, potentially contributing to overdiagnosis. The researchers used cancer registry data and developed models to identify patients with a very low risk of mortality.
The study analyzed DNA methylation in skin tumor samples, revealing correlations between changes in proteins regulating the organism and prognosis. The results identified potential markers of patient survival and suggested a new route for understanding melanoma subtypes.
Researchers found that certain fungal species in tumors are linked to inflammation and reduced cell-to-cell adhesion, features associated with late-stage cancer spread. High levels of these fungi may serve as biomarkers for metastasis risk and lead to more effective treatment choices.
A team from UNIGE and HUG identified a protein regulation mechanism that reduces melanoma cells' capacity to adapt and resist treatment. They found that targeting this mechanism with an enzyme inhibitor reduces therapeutic resistance in all melanoma cells.
Researchers found that Merkel cell carcinoma (MCC) Glypican-3 (GPC3) is expressed in nearly 70% of MCC tumors and up to 90% of MCPyV-negative cases. GPC3 expression is associated with worse prognosis, including increased risk of death from MCC. This makes GPC3 a promising target for chimeric antigen receptor T cell therapy.
Researchers at TIBI developed a minimally invasive method for targeted delivery of immunotherapeutic treatments, resulting in slower tumor growth and higher activation of T-cells. The injectable gelatin biomaterial containing silicate nanoplatelets showed sustained drug release and controlled ICI delivery.
Researchers discovered cancer cells produce a unique collagen that alters the tumor microbiome and promotes cancer progression. Loss of this collagen reduces cancer cell proliferation and boosts anti-tumor immune response, offering a potential therapeutic strategy.
New research reveals that age-induced changes in lung fibroblasts reactivate dormant melanoma cells, promoting growth and metastasis. The study found that WNT5A signaling pathway regulates tumor cell dormancy and metastasis initiation, with increased sFRP1 secretion facilitating reactivation in the aged lung.